5 stories found
Space startup SciSparc has appointed Professor Carmel Domshlak to its scientific advisory board to guide its agentic artificial intelligence initiatives. The move underscores the company’s strategic focus on integrating advanced AI into its space technology development.
SciSparc's stock more than doubled after NeuroThera received conditional approval for its CliniQuantum deal, signaling a significant market reaction.
A subsidiary of SciSparc has published a patent application for an MDMA combination, indicating potential advancements in pharmaceutical research.
SciSparc has announced a 1-for-9 reverse share split for its shares.
The collaboration between NeuroThera-Clearmind and SciSparc is advancing MDMA-N-acylethanolamines intellectual property for treating PTSD, supported by increasing U.S. federal interest in psychedelic innovation.